Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Yahoo! Finance
Net Cash Used in Operating Activities: $8.6 million for Q3 2024, significantly lower than $46.1 million in Q3 2023. Collaboration Revenue: $12.6 million for Q3 2024, up from $7.7 million in Q3 2023. Research and Development Expenses: $14.8 million for Q3 2024, down from $30.5 million in Q3 2023. General and Administrative Expenses: $9.9 million for Q3 2024, down from $12.9 million in Q3 2023. Net Loss: $11.5 million for Q3 2024, compared to $41.7 million in Q3 2023. Warning! GuruFocus has detected 8 Warning Signs with MRSN. Release Date: November 13, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Mersana Therapeutics Inc ( NASDAQ:MRSN ) made significant progress in their Phase I clinical trials for XMT-1660 and XMT-2056, with dose escalation ongoing and no maximum tolerated dose established yet. The company achieved multiple milestones in research collaborations and maintained a strong balance sheet, position
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsGlobeNewswire
- Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024GlobeNewswire
- SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
MRSN
Earnings
- 11/13/24 - Beat
MRSN
Sec Filings
- 11/15/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- MRSN's page on the SEC website